Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

FDA clears POC instrument for fentanyl testing

April 2023—Shenzhen Superbio Technology has received FDA clearance for the Ryan immunofluorescence analyzer, a point-of-care instrument for in vitro diagnostic use only. Carolina Liquid Chemistries Corp. will distribute the analyzer and fentanyl urine detection kit in partnership with Bioeasy USA. The fentanyl detection kit is intended for the qualitative detection of fentanyl in human urine at a cutoff concentration of 1 ng/mL. It is intended for use with the Ryan analyzer, which provides results in less than six minutes.

 

BD introduces Rhapsody HT Xpress system

April 2023—BD introduced the BD Rhapsody HT Xpress system for single-cell multiomics analysis. The system enables users to isolate, barcode, and analyze single cells at a high sample throughput—up to eight times more cells, BD says, than prior versions of its single-cell analyzers. Users can analyze multiple samples and different cell sizes and types, such as stem cells or cancer cells, at the same time.

Laboratory billing services provider

April 2023—Laboratory Billings is a revenue cycle management firm that aims to help laboratories achieve a higher first-pass claims rate and reduce accounts receivable. The company offers medical billing services to clinical and reference laboratories and shares real-time analytics about the revenue cycle. “We help laboratories become financially resilient and reduce the complexities in the administrative workflows,” according to a company statement. “Our billing and coding experts possess in-depth understanding of the revenue cycle management.” More information about the company is available at https://laboratorybillings.com.

 

Quest unveils transplant diagnostic services

April 2023—Quest Diagnostics unveiled Quest Advanced Specialized Transplant Services, designed to expand access to laboratory tests for transplanting solid organ, human cells, and tissue. Quest says its new offering features a menu of more than 170 specialized transplant and infectious disease tests, longitudinal trends analysis of test results in the electronic medical record, and support services that include medical consultation. Patients can access Quest’s network of 2,100 patient service centers and 5,000 mobile and at-home phlebotomists to support patient-compliant pre- and post-transplant testing. The services are available to recipients and living donors across the United States, excluding Alaska and Hawaii.

 

Verichem reference materials for triglyceride assays

April 2023—Verichem Laboratories released ready-to-use reference materials for use with calibration verification testing of triglyceride assays. The product is available in a five-level standard kit and an optional, standalone, ultra-high sixth level, with levels ranging from 10 to 1,250 mg/dL. Tricglyceride values are established by gravimetric weight of glycerol expressed as triolein.

 

Verichem Matrix Plus chemistry reference materials

April 2024—Verichem Laboratories liquid-stable Matrix Plus chemistry reference materials for the calibration verification of wet chemistry assays are now available. The multilevel kit, along with an optional and standalone level F, supports overall system quality control and CLIA compliance. The six-level set of materials contains seven individual chemistry analyte components covering 48 separate and individual concentration levels.

 

Visby gets FDA clearance, CLIA waiver for sexual health test

April 2023—Visby Medical has received 510(k) clearance and was granted a CLIA waiver from the FDA for its second-generation Sexual Health test. The point-of-care test uses PCR technology to detect sexually transmitted infections caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Visby says the new device features improvements in workflow, manufacturability, and reliability. Test accuracy is about 97 percent and results are available in less than 30 minutes.

 

FDA clears Leica Biosystems MMR antibody panel

April 2023—Leica Biosystems announced FDA 510(k) clearance of the Bond mismatch repair antibody panel for use in screening patients who have colorectal cancer for the identification of Lynch syndrome. The panel is for in vitro diagnostic use on Leica’s Bond-III and Bond-Max immunohistochemistry automated instruments. Turnaround time is 2.5 hours on the Bond-III and about 3.5 hours on the Bond-Max.

 

Enzo Biochem to sell clinical lab to Labcorp

April 2024—Enzo Biochem announced it has entered into an agreement in which Labcorp will acquire the assets of Enzo’s clinical laboratory division, Enzo Clinical Labs. Labcorp said the acquistion will bolster its commitment to the New York tristate health care communities. Completion of the sale is contingent on approval by Enzo’s shareholders and other customary closing conditions.

 

Qiagen, Servier to develop CDx for acute myeloid leukemia drug

April 2023—Qiagen has entered into a strategic partnership with Servier to develop a companion diagnostic test for Tibsovo (ivosidenib), an isocitrate dehydrogenase-1 inhibitor indicated for the treatment of acute myeloid leukemia. Under the agreement, Qiagen will develop and validate a real-time in vitro PCR test that can be used to detect IDH1 gene mutations in patients with AML in whole blood and bone marrow aspirates. The companion diagnostic will run on Qiagen’s Rotor-Gene Q MDx instrument.

 

MARKETPLACE

TRENDING